Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: Results from a prospective, randomized trial

Journal of the American Society of Nephrology

Volumn 16, Issue 8, 2005, Pages 2509-2516

  Hazzan, Marc ^a,b   Labalette, Myriam ^a   Copin, Marie Christine ^a   Glowacki, François ^a   Provôt, François ^a   Pruv, François René ^a   Noël, Christian ^a  

^a Regional University affiliated hospital of Lille   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

EID: 28444454862     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005030312     Document Type: Article

References (35)

1. Kasiske BL, Chakkera HA, Louis TA, Ma JZ: A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 11: 1910-1917, 2000
2. European Mycophenolate Mofetil Cooperative Study Group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for the prevention of acute rejection. Lancet 345: 1321-1325, 1995
3. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61: 1029-1037, 1996
4. Sollinger HW: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60: 225-232, 1995
5. Hazzan M, Bourdon F, Dracon M, Lelievre G, Noel C: Contribution of mycophenolate mofetil after withdrawal of cyclosporine to toxicity in kidney transplantation. Transplant Proc 30: 2809-2810, 1998
6. Ducloux D, Fournier V, Bresson-Vautrin C, Rebibou JM, Billerey C, Saint-Hillier Y, Chalopin JM: Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity: A preliminary report. Transplantation 65: 1504-1506, 1998
7. Houde I, Isenring P, Boucher D, Noel R, Lachanche JG: Mycophenolate mofetil, an alternative to cyclosporine A for long-term immunosuppression in kidney transplantation? Transplantation 70: 1251-1253, 2000
8. Schrama YC, Joles JA, van Tol A, Boer P, Koomans HA, Hene RJ: Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients. Transplantation 69: 376-383, 2000
9. Smak Gregoor PJ, van Gelder T, van Besouw NM, van der Mast BJ, IJzermans JN, Weimar W: Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Transplantation 70: 143-148, 2000
10. Thervet E, Morelon E, Ducloux D, Bererhi L, Noel LH, Janin A, Bedrossian J, Puget S, Chalopin JM, Mihatsch M, Legendre C, Kreis H: Cyclosporine withdrawal in stable renal transplant recipients after azathioprine- mycophenolate mofetil conversion. Clin Transplant 14: 561-566, 2000
11. Abramowicz D, Manas D, Lao M, Vanrenterghem Y, Del Castillo D, Wijngaard P, Fung S; Cyclosporine Withdrawal Study Group: Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: A randomized, controlled study. Transplantation 74: 1725-1734, 2002
12. Smak Gregoor PJ, de Sevaux RG, Ligtenberg G, Hoitsma AJ, Hene RJ, Weimar W, Hilbrands LB, van Gelder T: Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: A randomized, prospective, multicenter study. J Am Soc Nephrol 13: 1365-1373, 2002
13. Schnuelle P, van der Heide JH, Tegzess A, Verburgh CA, Paul LC, van der Woude FJ, de Fijter JW: Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 13: 536-543, 2002
14. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Yamaguchi Y, et al: The Banff 97 working classification of renal allograft pathology. Kidney Int 55: 713-723, 1999
15. Basadonna GP, Matas AJ, Gillingham KJ, Payne WD, Dunn DL, Sutherland DE, Gores PF, Gruessner RW, Najarian JS: Early versus late acute renal allograft rejection: Impact on chronic rejection. Transplantation 55: 993-995, 1993
16. Joseph JT, Kingsmore DB, Junor BJ, Briggs JD, Mun Woo Y, Jaques BC, Hamilton DN, Jardine AG, Jindal RM: The impact of late acute rejection after cadaveric kidney transplantation. Clin Transplant 15: 221-227, 2001
17. Anjum S, Andany MA, McClean JC, Danielson B, Kasiske BL: Defining the risk of elective cyclosporine withdrawal in stable kidney transplant recipients. Am J Transplant 2: 179-185, 2002
18. van Besouw NM, van der Mast BJ, de Kuiper P, Smak Gregoor PJ, Vaessen LM, Ijzermans JN, van Gelder T, Weimar W: Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced. Transplantation 70: 136-143, 2000
19. Meehan SM, Siegel CT, Aronson AJ, Bartosh SM, Thistle-thwaite JR, Woodle ES, Haas M: The relationship of untreated borderline infiltrates by the Banff criteria to acute rejection in renal allograft biopsies. J Am Soc Nephrol 10: 1806-1814, 1999
20. Schweitzer EJ, Drachenberg CB, Anderson L, Papadimetriou JC, Kuo PC, Johnson LB, Klassen DK, Hoehn-Saric E, Weir MR, Bartlett ST: Significance of the Banff borderline biopsy. Am J Kidney Dis 28: 585-588, 1996
21. Saad R, Gritsch HA, Shapiro R, Jordan M, Vivas C, Scantlebury V, Demetris AJ, Randhawa P: Clinical significance of renal allograft biopsies with "borderline changes," as defined in the Banff schema. Transplantation 64: 992-995, 1997
22. Papadimitriou J, Drachenberg C, Anderson L, Bartlett S, Johnson L, Klassen D, Hoehn-Saric E, Weir M, Schweitzer E: Follow-up of patients with borderline changes in renal allograft biopsies: Clinical outcome and evaluation of other histological features in addition to tubulitis. Transplant Proc 28: 517-518, 1996
23. Palomar R, Ruiz JC, Val-Bernal F, Escallada R, Rodrigo E, Cotorruelo J, Heras M, Arias M: Borderline changes in kidney transplantation: Evolution of treated cases versus nontreated. Transplant Proc 31: 2314, 1999
24. Lorriaux C, MacGregor B, Dijoud F, Cahen R, Touraine JL, Pouteil-Nobel C: Should patients with "borderline" lesions of Banff criteria be treated by renal transplantation? Transplant Proc 30: 2823-2824, 1998
25. Roberts IS, Reddy S, Russell C, Davies DR, Friend PJ, Handa AI, Morris PJ: Subclinical rejection and borderline changes in early protocol biopsy specimens after renal transplantation. Transplantation 77: 1194-1198, 2004
26. Shapiro R, Randhawa P, Jordan ML, Scantlebury VP, Vivas C, Jain A, Corry RJ, McCauley J, Johnston J, Donaldson J, Gray EA, Dvorchik I, Hakala TR, Fung JJ, Starzl TE: An analysis of early renal transplant protocol biopsies-The high incidence of subclinical tubulitis. Am J Transplant 1: 47-50, 2001
27. Kanetsuna Y, Yamaguchi Y, Toma H, Tanabe K: Histological evaluation of renal allograft protocol biopsies in the early period and 1 year after transplantation. Clin Transplant 17: 25-29, 2003
28. van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, Hene RJ, Verpooten GA, Navarro MT, Hale MD, Nicholls AJ: A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68: 261-266, 1999
29. Pillans PI, Rigby RJ, Kubler P, Willis C, Salm P, Tett SE, Taylor PJ: A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients. Clin Biochem 34: 77-81, 2001
30. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O, Zimmerhackl LB, Oellerich M, Tonshoff B: The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: A report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 13: 759-768, 2002
31. Kiberd BA, Lawen J, Fraser AD, Keough-Ryan T, Belitsky P: Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant 4: 1079-1083, 2004
32. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP, for the Sirolimus Renal Function Study Group: Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 74: 1560-1567, 2002
33. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J: Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72: 777-786, 2001
34. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP: Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 62: 311-318, 2002
35. van Hest RM, Mathot RA, Vulto AG, Le Meur Y, van Gelder T: Mycophenolic acid in diabetic renal transplant recipients: Pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 26: 620-625, 2004